Despite looming tariffs, medtech giants Abbott and Johnson & Johnson told investors they would maintain their annual profit forecast, with Abbott announcing it would invest $500m in US manufacturing and research projects.
Abbott CEO Robert Ford told investors during a call yesterday that the medical device company was considering raising its profit guidance, emphasizing Abbott’s strong performance to start the year, but...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?